Selvita (WAR:SLV) Beneish M-Score: -3.06 (As of Jun. 27, 2026)


WAR:SLV Selvita SA WAR:SLV
81 GF Score
Price zł31.60
GF Value zł58.46
Valuation Significantly Undervalued
! 4 Warning Signs
View Full Analysis

What is Selvita Beneish M-Score?

Selvita WAR:SLV +3.27% 81 Beneish M-Score is -3.06 as of Jun. 27, 2026. GuruFocus rates WAR:SLV with a GF Score™ of 81/100 and a GF Value™ of zł58.46 (Significantly Undervalued). The stock has 4 warning signs investors should review. Among 195 Medical Diagnostics & Research companies, Selvita ranks better than 75.38% on this metric.

The zones of discrimination for M-Score is as such:

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator.
An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Good Sign:

Beneish M-Score -3.06 no higher than -1.78, which implies that the company is unlikely to be a manipulator.

The historical rank and industry rank for Selvita's Beneish M-Score or its related term are showing as below:

WAR:SLV' s Beneish M-Score Range Over the Past 10 Years
Min: -3.06   Med: -2.52   Max: -0.3
Current: -3.06

During the past 11 years, the highest Beneish M-Score of Selvita was -0.30. The lowest was -3.06. And the median was -2.52.


Selvita Beneish M-Score Historical Data

* Premium members only.

The historical data trend for Selvita's Beneish M-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Selvita Beneish M-Score Chart

Selvita Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Beneish M-Score
Get a 7-Day Free Trial Premium Member Only Premium Member Only -0.84 -2.47 -2.56 -2.83 -3.00

Selvita Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Beneish M-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -2.63 -2.92 -2.93 -3.00 -3.06

WAR:SLV vs TMO, DHR, IDXX: Beneish M-Score Comparison

For the Diagnostics & Research subindustry, Selvita's Beneish M-Score, along with its competitors' market caps and Beneish M-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Selvita Beneish M-Score vs Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Selvita's Beneish M-Score distribution charts can be found below:

* The bar in red indicates where Selvita's Beneish M-Score falls into.


WAR:SLV
81GF Score
Selvita SA WAR:SLV
Beneish M-Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Selvita Beneish M-Score Calculation

The M-score was created by Professor Messod Beneish. Instead of measuring the bankruptcy risk (Altman Z-Score) or business trend (Piotroski F-Score), M-score can be used to detect the risk of earnings manipulation. This is the original research paper on M-score.

The M-Score Variables:

The M-score of Selvita for today is based on a combination of the following eight different indices:

M=-4.84+0.92 * DSRI+0.528 * GMI+0.404 * AQI+0.892 * SGI+0.115 * DEPI
=-4.84+0.92 * 1.031+0.528 * 0.9848+0.404 * 1.0168+0.892 * 0.9828+0.115 * 0.9055
-0.172 * SGAI+4.679 * TATA-0.327 * LVGI
-0.172 * 1+4.679 * -0.129826-0.327 * 0.9139
=-3.06

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Mar26) TTM:Last Year (Mar25) TTM:
Total Receivables was zł78.3 Mil.
Revenue was 75.825 + 92.534 + 88.023 + 93.484 = zł349.9 Mil.
Gross Profit was 59.183 + 76.135 + 71.785 + 73.386 = zł280.5 Mil.
Total Current Assets was zł120.5 Mil.
Total Assets was zł584.1 Mil.
Property, Plant and Equipment(Net PPE) was zł209.4 Mil.
Depreciation, Depletion and Amortization(DDA) was zł53.6 Mil.
Selling, General, & Admin. Expense(SGA) was zł0.0 Mil.
Total Current Liabilities was zł120.8 Mil.
Long-Term Debt & Capital Lease Obligation was zł110.6 Mil.
Net Income was -5.449 + 7.344 + -0.936 + -4.609 = zł-3.7 Mil.
Non Operating Income was 0 + 0 + 0 + 0 = zł0.0 Mil.
Cash Flow from Operations was 9.174 + 29.013 + 21.922 + 12.074 = zł72.2 Mil.
Total Receivables was zł77.3 Mil.
Revenue was 90.208 + 97.431 + 88.225 + 80.112 = zł356.0 Mil.
Gross Profit was 72.113 + 78.103 + 69.338 + 61.509 = zł281.1 Mil.
Total Current Assets was zł121.3 Mil.
Total Assets was zł632.6 Mil.
Property, Plant and Equipment(Net PPE) was zł240.6 Mil.
Depreciation, Depletion and Amortization(DDA) was zł54.5 Mil.
Selling, General, & Admin. Expense(SGA) was zł0.0 Mil.
Total Current Liabilities was zł122.3 Mil.
Long-Term Debt & Capital Lease Obligation was zł151.9 Mil.




1. DSRI = Days Sales in Receivables Index

Measured as the ratio of Revenue in Total Receivables in year t to year t-1.

A large increase in DSR could be indicative of revenue inflation.

DSRI=(Receivables_t / Revenue_t) / (Receivables_t-1 / Revenue_t-1)
=(78.295 / 349.866) / (77.267 / 355.976)
=0.223786 / 0.217057
=1.031

2. GMI = Gross Margin Index

Measured as the ratio of gross margin in year t-1 to gross margin in year t.

Gross margin has deteriorated when this index is above 1. A firm with poorer prospects is more likely to manipulate earnings.

GMI=GrossMargin_t-1 / GrossMargin_t
=(GrossProfit_t-1 / Revenue_t-1) / (GrossProfit_t / Revenue_t)
=(281.063 / 355.976) / (280.489 / 349.866)
=0.789556 / 0.801704
=0.9848

3. AQI = Asset Quality Index

AQI is the ratio of asset quality in year t to year t-1.

Asset quality is measured as the ratio of non-current assets other than Property, Plant and Equipment to Total Assets.

AQI=(1 - (CurrentAssets_t + PPE_t) / TotalAssets_t) / (1 - (CurrentAssets_t-1 + PPE_t-1) / TotalAssets_t-1)
=(1 - (120.498 + 209.406) / 584.111) / (1 - (121.255 + 240.606) / 632.618)
=0.435203 / 0.427994
=1.0168

4. SGI = Sales Growth Index

Ratio of Revenue in year t to sales in year t-1.

Sales growth is not itself a measure of manipulation. However, growth companies are likely to find themselves under pressure to manipulate in order to keep up appearances.

SGI=Sales_t / Sales_t-1
=Revenue_t / Revenue_t-1
=349.866 / 355.976
=0.9828

5. DEPI = Depreciation Index

Measured as the ratio of the rate of Depreciation, Depletion and Amortization in year t-1 to the corresponding rate in year t.

DEPI greater than 1 indicates that assets are being depreciated at a slower rate. This suggests that the firm might be revising useful asset life assumptions upwards, or adopting a new method that is income friendly.

DEPI=(Depreciation_t-1 / (Depreciaton_t-1 + PPE_t-1)) / (Depreciation_t / (Depreciaton_t + PPE_t))
=(54.485 / (54.485 + 240.606)) / (53.639 / (53.639 + 209.406))
=0.184638 / 0.203916
=0.9055

Note: If the Depreciation, Depletion and Amortization data is not available, we assume that the depreciation rate is constant and set the Depreciation Index to 1.

6. SGAI = Sales, General and Administrative expenses Index

The ratio of Selling, General, & Admin. Expense(SGA) to Sales in year t relative to year t-1.

SGA expenses index > 1 means that the company is becoming less efficient in generate sales.

SGAI=(SGA_t / Sales_t) / (SGA_t-1 /Sales_t-1)
=(0 / 349.866) / (0 / 355.976)
=0 / 0
=1

7. LVGI = Leverage Index

The ratio of total debt to Total Assets in year t relative to yeat t-1.

An LVGI > 1 indicates an increase in leverage

LVGI=((LTD_t + CurrentLiabilities_t) / TotalAssets_t) / ((LTD_t-1 + CurrentLiabilities_t-1) / TotalAssets_t-1)
=((110.603 + 120.765) / 584.111) / ((151.862 + 122.323) / 632.618)
=0.396103 / 0.433413
=0.9139

8. TATA = Total Accruals to Total Assets

Total accruals calculated as the change in working capital accounts other than cash less depreciation.

TATA=(IncomefromContinuingOperations_t - CashFlowsfromOperations_t) / TotalAssets_t
=(NetIncome_t - NonOperatingIncome_t - CashFlowsfromOperations_t) / TotalAssets_t
=(-3.65 - 0 - 72.183) / 584.111
=-0.129826

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator. An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Selvita has a M-score of -3.06 suggests that the company is unlikely to be a manipulator.

Frequently Asked Questions Learn more about Beneish M-Score →
What does a Beneish M-Score of -3.06 mean?
Selvita (WAR:SLV) has a Beneish M-Score of -3.06 as of Jun. 27, 2026. The Beneish M-score measures the likelihood of earnings manipulation. View historical data on Selvita and its competitors. According to the industry distribution chart, Selvita ranks #48 out of 195 companies in the Medical Diagnostics & Research industry, placing it in the top 24.6%.
Is Selvita's Beneish M-Score too high?
Selvita's current Beneish M-Score is -3.06. Based on the distribution chart, Selvita ranks #48 out of 195 companies in the Medical Diagnostics & Research industry, which is in the top quartile — a strong position relative to peers. Overall, Selvita has a GF Score™ of 81/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Selvita's Beneish M-Score compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Selvita ranks #48 out of 195 companies for Beneish M-Score. This places Selvita in the top 25% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Beneish M-Score for a Medical Diagnostics & Research company?
A good Beneish M-Score depends on the Medical Diagnostics & Research industry context. However, Beneish M-Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Beneish M-Score mean?
A high Beneish M-Score can signal that a stock is expensive relative to its fundamentals. The Beneish M-score measures the likelihood of earnings manipulation. View historical data on Selvita and its competitors. Selvita's current Beneish M-Score is -3.06. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Selvita stock overvalued right now?
Based on GuruFocus' analysis, Selvita (WAR:SLV) is currently considered Significantly Undervalued. The stock's GF Value™ is zł58.46, compared to a current price of zł31.60 — trading 45.9% below its estimated fair value. The current Beneish M-Score is -3.06. Selvita's overall GF Score™ is 81/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Beneish M-Score calculated?
Beneish M-Score is calculated from a company's financial statements. For Selvita (WAR:SLV), the current Beneish M-Score is -3.06 as of Jun. 27, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Selvita (WAR:SLV) Overvalued in 2026?

Based on GuruFocus' analysis, Selvita stock appears to be undervalued. The current stock price of zł31.60 is trading 45.9% below its estimated GF Value™ of zł58.46. GuruFocus considers Selvita to be Significantly Undervalued.

Key valuation signals for WAR:SLV:

  • Beneish M-Score: -3.06
  • GF Value™: zł58.46 vs. price of zł31.60 (45.9% below fair value)
  • GF Score™: 81/100 with 4 warning signs

No single metric tells the full story. See the WAR:SLV stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Selvita Business Description

Other Exchanges 787:Germany
Address Bobrzynskiego 14, Park Life Science, Krakow, POL, 30-348
Selvita SA is a Poland based parent company of Selvita Group is one of the largest preclinical contract research organizations in Europe. It also develops bioinformatics solutions supporting innovative projects at preclinical stages. It also provides services provided to external contractors are in the field of chemistry, analytics, regulatory, biochemistry and cell biology and also the integrated research and development projects.
81GF Score

Get the complete analysis for WAR:SLV

Beneish M-Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

zł31.60
Price
zł58.46
GF Value